Department of Pathology and Laboratory Medicine, UMDNJ-New Jersey Medical School, Newark, New Jersey 07101-1709, USA.
J Cell Physiol. 2011 May;226(5):1232-40. doi: 10.1002/jcp.22449.
Metabolites and derivatives of vitamin D are well-known inducers of monocytic differentiation, but the mechanistic basis for their action is not fully elucidated. Here we show that the product of protooncogene Cot1 represses the monocytic phenotype in human acute myeloid leukemia (AML) cells induced to differentiate by 1,25-dihydroxyvitamin D(3) (1,25D), even though the expression of cellular Cot1 increases early in the process of 1,25D-induced differentiation. Interestingly, the expression of the two members of the Kinase Suppressor of Ras (KSR) family of molecular scaffolds, known to be positive regulators of Ras signaling and of 1,25D-induced differentiation, increases in parallel with Cot1 in 1,25D-treated cells. However, KSR1/2 are negatively regulated by Cot1, as determined by transfection of siCot1, and confirmed by a reverse effect of ectopic expression of Cot1. The effect of Cot1 in AML cells appears to be cell-type specific, as previous reports in other cell types found KSR-2 to be a negative regulator of Cot1, a reverse relationship. Also in contrast to findings in other cells, in AML cells Cot1 exerts negative control on the MAP kinase pathways, since siCot1 increases the levels of activated Raf1, p90RSK, JNK1, c-jun, and p38, though not of MEK/ERK. These findings have implications for therapy of AML, since in AML cells active MAPKs hasten cell differentiation, and specific pharmacological inhibitors of Cot1 kinase activity have recently became available, thus making Cot1 a "druggable" target.
维生素 D 的代谢产物和衍生物是众所周知的单核细胞分化诱导剂,但它们作用的机制基础尚未完全阐明。在这里,我们表明原癌基因 Cot1 的产物在被 1,25-二羟维生素 D(1,25D)诱导分化的人类急性髓系白血病(AML)细胞中抑制单核细胞表型,尽管 Cot1 的表达在 1,25D 诱导分化的过程中早期增加。有趣的是,两种激酶抑制剂 Ras (KSR)家族分子支架的成员的表达,已知是 Ras 信号和 1,25D 诱导分化的正调节剂,与 Cot1 在 1,25D 处理的细胞中平行增加。然而,正如 Cot1 的 siRNA 转染所确定的,以及 Cot1 的异位表达的相反效果所证实的,KSR1/2 被 Cot1 负调节。Cot1 在 AML 细胞中的作用似乎是细胞类型特异性的,因为先前在其他细胞类型中的报道发现 KSR-2 是 Cot1 的负调节剂,这是一种相反的关系。也与其他细胞中的发现相反,在 AML 细胞中 Cot1 对 MAP 激酶途径施加负控制,因为 Cot1 的 siRNA 增加了激活的 Raf1、p90RSK、JNK1、c-jun 和 p38 的水平,尽管不是 MEK/ERK。这些发现对 AML 的治疗具有重要意义,因为在 AML 细胞中,活跃的 MAPKs 加速细胞分化,并且 Cot1 激酶活性的特异性药理学抑制剂最近已经可用,从而使 Cot1 成为“可用药”的靶标。